These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 24127184)

  • 21. Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor.
    Rioja I; Hughes FJ; Sharp CH; Warnock LC; Montgomery DS; Akil M; Wilson AG; Binks MH; Dickson MC
    Arthritis Rheum; 2008 Aug; 58(8):2257-67. PubMed ID: 18668547
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Disease activity improvement in rheumatoid arthritis treated with tumor necrosis factor-α inhibitors correlates with increased soluble Fas levels.
    Romano E; Terenzi R; Manetti M; Peruzzi F; Fiori G; Nacci F; Bellando-Randone S; Matucci-Cerinic M; Guiducci S
    J Rheumatol; 2014 Oct; 41(10):1961-5. PubMed ID: 25179850
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection.
    Ferri C; Ferraccioli G; Ferrari D; Galeazzi M; Lapadula G; Montecucco C; Triolo G; Valentini G; Valesini G;
    J Rheumatol; 2008 Oct; 35(10):1944-9. PubMed ID: 18688917
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor necrosis factor blockade differentially affects innate inflammatory and Th17 cytokines in rheumatoid arthritis.
    Zivojinovic SM; Pejnovic NN; Sefik-Bukilica MN; Kovacevic LV; Soldatovic II; Damjanov NS
    J Rheumatol; 2012 Jan; 39(1):18-21. PubMed ID: 22133625
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis.
    Braun-Moscovici Y; Markovits D; Zinder O; Schapira D; Rozin A; Ehrenburg M; Dain L; Hoffer E; Nahir AM; Balbir-Gurman A
    J Rheumatol; 2006 Mar; 33(3):497-500. PubMed ID: 16511906
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
    Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
    J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationship between pack-year history of smoking and response to tumor necrosis factor antagonists in patients with rheumatoid arthritis.
    Mattey DL; Brownfield A; Dawes PT
    J Rheumatol; 2009 Jun; 36(6):1180-7. PubMed ID: 19447930
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection.
    Parke FA; Reveille JD
    Arthritis Rheum; 2004 Oct; 51(5):800-4. PubMed ID: 15478165
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study.
    Mancarella L; Bobbio-Pallavicini F; Ceccarelli F; Falappone PC; Ferrante A; Malesci D; Massara A; Nacci F; Secchi ME; Manganelli S; Salaffi F; Bambara ML; Bombardieri S; Cutolo M; Ferri C; Galeazzi M; Gerli R; Giacomelli R; Grassi W; Lapadula G; Cerinic MM; Montecucco C; Trotta F; Triolo G; Valentini G; Valesini G; Ferraccioli GF;
    J Rheumatol; 2007 Aug; 34(8):1670-3. PubMed ID: 17611987
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register.
    Karlsson JA; Kristensen LE; Kapetanovic MC; Gülfe A; Saxne T; Geborek P
    Rheumatology (Oxford); 2008 Apr; 47(4):507-13. PubMed ID: 18304941
    [TBL] [Abstract][Full Text] [Related]  

  • 31. IgG antibodies to type II collagen reflect inflammatory activity in patients with rheumatoid arthritis.
    Kim WU; Yoo WH; Park W; Kang YM; Kim SI; Park JH; Lee SS; Joo YS; Min JK; Hong YS; Lee SH; Park SH; Cho CS; Kim HY
    J Rheumatol; 2000 Mar; 27(3):575-81. PubMed ID: 10743792
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register.
    Kristensen LE; Kapetanovic MC; Gülfe A; Söderlin M; Saxne T; Geborek P
    Rheumatology (Oxford); 2008 Apr; 47(4):495-9. PubMed ID: 18316338
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors.
    Genovese MC; Fleischmann RM; Greenwald M; Satterwhite J; Veenhuizen M; Xie L; Berclaz PY; Myers S; Benichou O
    Ann Rheum Dis; 2013 Sep; 72(9):1461-8. PubMed ID: 23268367
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The reason for discontinuation of the first tumor necrosis factor (TNF) blocking agent does not influence the effect of a second TNF blocking agent in patients with rheumatoid arthritis.
    Blom M; Kievit W; Fransen J; Kuper IH; den Broeder AA; De Gendt CM; Jansen TL; Brus HL; van de Laar MA; van Riel PL
    J Rheumatol; 2009 Oct; 36(10):2171-7. PubMed ID: 19723902
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.
    Markenson JA; Gibofsky A; Palmer WR; Keystone EC; Schiff MH; Feng J; Baumgartner SW
    J Rheumatol; 2011 Jul; 38(7):1273-81. PubMed ID: 21572150
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical significance of synovial lymphoid neogenesis and its reversal after anti-tumour necrosis factor alpha therapy in rheumatoid arthritis.
    Cañete JD; Celis R; Moll C; Izquierdo E; Marsal S; Sanmartí R; Palacín A; Lora D; de la Cruz J; Pablos JL
    Ann Rheum Dis; 2009 May; 68(5):751-6. PubMed ID: 18495732
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Circulating leptin and adiponectin concentrations during tumor necrosis factor blockade in patients with active rheumatoid arthritis.
    Popa C; Netea MG; de Graaf J; van den Hoogen FH; Radstake TR; Toenhake-Dijkstra H; van Riel PL; van der Meer JW; Stalenhoef AF; Barrera P
    J Rheumatol; 2009 Apr; 36(4):724-30. PubMed ID: 19273452
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The relationship between synovial lymphocyte aggregates and the clinical response to infliximab in rheumatoid arthritis: a prospective study.
    Klaasen R; Thurlings RM; Wijbrandts CA; van Kuijk AW; Baeten D; Gerlag DM; Tak PP
    Arthritis Rheum; 2009 Nov; 60(11):3217-24. PubMed ID: 19877042
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumour necrosis factor antagonists improve disease activity but not arterial stiffness in rheumatoid arthritis.
    Van Doornum S; McColl G; Wicks IP
    Rheumatology (Oxford); 2005 Nov; 44(11):1428-32. PubMed ID: 16076882
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis.
    Popa C; van den Hoogen FH; Radstake TR; Netea MG; Eijsbouts AE; den Heijer M; van der Meer JW; van Riel PL; Stalenhoef AF; Barrera P
    Ann Rheum Dis; 2007 Nov; 66(11):1503-7. PubMed ID: 17472994
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.